Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system

  • Authors:
    • Paweł Krawczyk
    • Marcin Nicoś
    • Tomasz Powrózek
    • Radosław Mlak
    • Marek Sawicki
    • Bożena Jarosz
    • Beata Pająk
    • Krzysztof Kucharczyk
    • Dariusz Stencel
    • Tomasz Trojanowski
    • Janusz Milanowski
  • View Affiliations

  • Published online on: July 26, 2013     https://doi.org/10.3892/ol.2013.1495
  • Pages: 1063-1067
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The HER2 (ErbB2/neu) protein is a member of the HER (ErbB) receptor family (EGFR, HER2, HER3 and HER4) that expresses tyrosine kinase activity in the intracellular domain. EGFR and HER2 overexpression is observed in numerous types of cancer, nevertheless, the susceptibility of patients with non‑small cell lung cancer (NSCLC) to therapy with EGFR and HER2 tyrosine kinase inhibitors (TKIs) depends on mutations present in the respective coding genes (driver mutations). In the present study, PCR and amplified DNA fragment length analysis (FLA) were used along with the multi‑temperature single‑strand conformation polymorphism (MSSCP) technique in order to identify the 12 base pair insertion in exon 20 of the HER2 gene in 143 patients with NSCLC metastasis to the central nervous system. The prevalence of the HER2 gene mutation was correlated with mutations in the EGFR and BRAF genes. The insertion in exon 20 of the HER2 gene was observed in a single 77‑year‑old, non‑smoking male, with poorly‑differentiated adenocarcinoma of the lung (1.5% of adenocarcinoma patients). No other genetic abnormalities were identified in this patient. In the therapy of NSCLC patients with HER2 gene mutations, drugs that inhibit the EGFR and HER2 receptors, for example afatinib, may be effective. The identification of other driving mutations in NSCLC cells appears to be key to the appropriate qualification of molecular targeted therapies.
View Figures
View References

Related Articles

Journal Cover

October 2013
Volume 6 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Krawczyk P, Nicoś M, Powrózek T, Mlak R, Sawicki M, Jarosz B, Pająk B, Kucharczyk K, Stencel D, Trojanowski T, Trojanowski T, et al: Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system. Oncol Lett 6: 1063-1067, 2013
APA
Krawczyk, P., Nicoś, M., Powrózek, T., Mlak, R., Sawicki, M., Jarosz, B. ... Milanowski, J. (2013). Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system. Oncology Letters, 6, 1063-1067. https://doi.org/10.3892/ol.2013.1495
MLA
Krawczyk, P., Nicoś, M., Powrózek, T., Mlak, R., Sawicki, M., Jarosz, B., Pająk, B., Kucharczyk, K., Stencel, D., Trojanowski, T., Milanowski, J."Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system". Oncology Letters 6.4 (2013): 1063-1067.
Chicago
Krawczyk, P., Nicoś, M., Powrózek, T., Mlak, R., Sawicki, M., Jarosz, B., Pająk, B., Kucharczyk, K., Stencel, D., Trojanowski, T., Milanowski, J."Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system". Oncology Letters 6, no. 4 (2013): 1063-1067. https://doi.org/10.3892/ol.2013.1495